Azstarys (Dexmethylphenidate/Serdexmethylphenidate) Shortage: What Providers and Prescribers Need to Know in 2026

Azstarys (serdexmethylphenidate/dexmethylphenidate, SDX/d-MPH) represents an innovative approach to ADHD pharmacotherapy — a fixed 70/30 molar ratio prodrug-immediate release combination that offers a smooth, extended pharmacokinetic profile. However, its brand-only status and niche market position create real access challenges for patients. This guide is written for psychiatrists, pediatricians, primary care physicians, and other clinicians prescribing Azstarys in 2026.

Current Availability Status of Azstarys (Early 2026)

Azstarys is NOT on the FDA's current drug shortage list as of early 2026. The manufacturer (Corium, a Sun Pharmaceutical company) has not formally reported a supply disruption. However, clinical reality diverges from this regulatory status:

Many pharmacies — particularly smaller independents and low-volume chains — do not routinely stock Azstarys

Patients continue to report difficulty filling prescriptions in some regions

The broader ADHD stimulant demand surge (which began in October 2022) continues to stress all methylphenidate-class supply chains

The DEA increased the aggregate production quota for methylphenidate by approximately 9% in October 2025, which should gradually ease supply constraints in 2026

Why Azstarys Is Structurally More Vulnerable to Access Challenges

Several pharmaceutical and regulatory factors make Azstarys more susceptible to access difficulties than older methylphenidate products:

Single manufacturer: As a brand-only product, Azstarys has only one manufacturer. Generic competition — which diversifies supply — is not expected until at least 2037.

Novel active pharmaceutical ingredient: Serdexmethylphenidate chloride is a distinct chemical entity. Its synthesis is more complex than standard methylphenidate formulations, adding manufacturing variables.

Pharmacy stocking patterns: Pharmacies stock medications based on prescription volume. Azstarys, with a smaller prescriber base than older ADHD medications, may not be routinely ordered by all pharmacies.

Pharmacokinetic Profile: What Makes Azstarys Unique

Understanding Azstarys's pharmacokinetics is essential to appropriate therapeutic substitution when it's unavailable:

The 30% immediate-release d-MPH component provides onset within 30 minutes of ingestion

The 70% serdexmethylphenidate (SDX) prodrug component is pharmacologically inactive until bioactivated in the lower gastrointestinal tract, providing gradual conversion to d-MPH over 12–13 hours

This results in a relatively smooth, sustained plasma concentration curve without the sharp biphasic peaks seen with bimodal-release formulations like Focalin XR

The SDX prodrug component requires GI activation and is pharmacologically inactive if snorted or injected — a Schedule IV substance despite the overall product being CII

When Azstarys Is Unavailable: Evidence-Based Substitution Strategies

When a patient cannot access Azstarys, the following substitution hierarchy is clinically rational:

Generic dexmethylphenidate ER (Focalin XR equivalent): The same active metabolite; bimodal-release profile. Do NOT substitute milligram-for-milligram — Azstarys and Focalin XR are not bioequivalent. Titrate from starting doses.

Lisdexamfetamine (generic Vyvanse): Also a prodrug-based once-daily stimulant but amphetamine-class. Generic is now widely available. For patients who respond well to the prodrug mechanism and once-daily dosing of Azstarys.

Methylphenidate ER (generic Concerta): Racemic methylphenidate extended-release. Broader prescriber familiarity, widely available as a generic.

Atomoxetine (generic Strattera): Non-stimulant option for patients with contraindications to stimulants or high abuse risk. Note 4–6 week onset to full effect.

Insurance and Prior Authorization Considerations

Azstarys coverage varies significantly across payers:

Many commercial plans cover Azstarys but require prior authorization and/or step therapy through generic methylphenidate or dexmethylphenidate formulations first

Some plans restrict coverage to patients under 17 years of age

Medicaid coverage varies by state — check your state formulary

The CoriumCares patient savings program offers $60 or less for commercially insured patients; $0 first prescription, $25 with insurance for refills, $50 without insurance

Key Prescribing Reminders for Azstarys

Azstarys is Schedule II CII — EPCS or written prescription required in most states; no phone-in to pharmacy

Do not substitute for other methylphenidate products milligram-for-milligram; pharmacokinetic profiles differ significantly

Capsules may be opened and contents sprinkled on applesauce or in 50 mL of water — all contents must be consumed within 10 minutes

Not recommended for patients under 6 years of age

Contraindicated with current or recent (within 14 days) MAOI use

Helping Your Patients Find Azstarys

Providers can recommend their patients use medfinder for providers to locate pharmacies with Azstarys in stock before writing the prescription. medfinder calls pharmacies to check real-time availability and texts the results to the patient — eliminating the frustrating cycle of prescriptions written to pharmacies that don't have the medication in stock. This is especially valuable for brand-only Schedule II stimulants like Azstarys.